Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the target spectrum of 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on the "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration of phosphoproteomic data refined drug-affected pathways, identified response markers, and strengthened rationale for combination treatments. We exemplify translational value by discovering SIK2 (salt-inducible kinase 2) inhibitors that modulate cytokine production in primary cells, by identifying drugs against the lung cancer survival marker MELK (maternal embryonic leucine zipper kinase), and by repurposing cabozantinib to treat FLT3-ITD-positive acute myeloid leukemia. This resource, available via the ProteomicsDB database, should facilitate basic, clinical, and drug discovery research and aid clinical decision-making.
PublisherAmerican Association for the Advancement of Science (AAAS)
Publishing PlaceWashington
University
University place
Faculty
Publication date0000-00-00
Application number
Application date0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing statusPeer reviewed
Institute(s)Research Unit Apoptosis in Hematopoetic Stem Cells (AHS) Core Facilty Pathology and Tissue Analytics (CF-PTA) Research Unit Analytical Pathology (AAP)